Unleashing the potential of online learning in Spain: An econometric analysis

Online learning and training continue gaining momentum worldwide resulting in the reduction of the traditional form of face-to-face education with its temporal and spatial limitations. Online education improves access to education and training, as witnessed during the Covid-19 pandemic. This article focuses on online education adoption in Spain. A representative survey on ICT use in households conducted annually by the Spanish National Institute of Statistics is used to construct a panel database for the years 2008–2020. The first objective is to provide an econometric model for adopting online education using this panel data. Next is to measure the effects of relevant observable individual socioeconomic variables on adoption. A Heckman selection model allows for estimating the impact of gender, age, education, digital skills, habitat, and income. The article also measures the effects of Covid-19 in 2020 on different population groups. The drivers and impediments have the expected signs and plausible sizes. The paper concludes with policy recommendations and suggestions for further research. © 2023 Elsevier Ltd

Optimization of the layout of meeting rooms, in the fight against COVID- 19, trough the web application sala planejada

Conscience, Responsibility and Solidarity, are important pillars to which large companies are guided in this scenario of combating the pandemic generated by COVID-19. In this paper, the application of optimization techniques is addressed though the Planned Room web application, motivated by the need for a safe return to work, respecting the social distancing criteria pointed out by the World Health Organization. The objective is to propose an optimized layout for the meeting rooms and other living spaces, maximizing the number of places available from the physical dimensions of the environments of the tables and chairs offered. The use of the Planned Room proved to be advantageous for generating an optimized plan with the coordinates foreseen for each chair and for guaranteeing the minimum distance necessary to avoid contagion among workers, which can be replicated to the other units of the company.

Data analysis and machine learning techniques in the analysis of car safes in Brazil during the Covid-19 pandemic

This study aims to analyze the impacts of Covid-19 on vehicle safes in Brazil, correlating these factors with semiconductors imports and economic indicators using Machine Learning models. For this, a collection and preparation of data took place before performing the exploratory analysis, and the developing of predictive models. This work is characterized as an applied and exploratory research, with a quantitative approach. The Python language was used to perform exploratory analysis and to create the models. The data used in this study were collected froco multiples sources of private companies, government, associations and research institutes.Three regression algorithms were used: Random Forest, Multi-Layer Perceptron and Multiple Linear Regression. The neural network presented the best results among the applied algorithms, reaching an R-2 of 82.01% in the test data set. After the exploratory analysis, we also noticed the high impact that semiconductors have on vehicle safes and the drastic effects caused by Covid-19 on the variables used in the study. With the model created, it is possible to predict the safes of vehicles in Brazil in a given month based on some economic indicators, semiconductor imports and the monthly deaths of Covid-19.

The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.

BACKGROUND: COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate and monitor well-being since COVID-19 in relation to work, lifestyle and support factors in oncology professionals 1 year on since the start of the pandemic. METHODS: An online, anonymous survey was conducted in February/March 2021 (Survey III). Key outcome variables included risk of poor well-being or distress (expanded Well-Being Index), feeling burnout (single item from expanded Well-Being Index), and job performance since COVID-19. Longitudinal analysis of responses to the series of three surveys since COVID-19 was carried out, and responses to job demands and resources questions were interrogated. SPSS V.26.0/V.27.0 and GraphPad Prism V9.0 were used for statistical analyses. RESULTS: Responses from 1269 participants from 104 countries were analysed in Survey III: 55% (n = 699/1269) female, 54% (n = 686/1269) >40 years, and 69% (n = 852/1230) of white ethnicity. There continues to be an increased risk of poor well-being or distress (n = 464/1169, 40%) and feeling burnout (n = 660/1169, 57%) compared with Survey I (25% and 38% respectively, P < 0.0001), despite improved job performance. Compared with the initial period of the pandemic, more participants report feeling overwhelmed with workload (45% versus 29%, P < 0.0001). There remain concerns about the negative impact of the pandemic on career development/training (43%), job security (37%). and international fellowship opportunities (76%). Alarmingly, 25% (n = 266/1086) are considering changing their future career with 38% (n = 100/266) contemplating leaving the profession. CONCLUSION: Oncology professionals continue to face increased job demands. There is now significant concern regarding potential attrition in the oncology workforce. National and international stakeholders must act immediately and work closely with oncology professionals to draw up future-proof recovery plans.

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.

BACKGROUND: The COVID-19 pandemic has resulted in significant changes to professional and personal lives of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration aimed to provide contemporaneous reports on the impact of COVID-19 on the lived experiences and well-being in oncology. METHODS: This online anonymous survey (July-August 2020) is the second of a series of global surveys launched during the course of the pandemic. Longitudinal key outcome measures including well-being/distress (expanded Well-being Index-9 items), burnout (1 item from expanded Well-being Index), and job performance since COVID-19 were tracked. RESULTS: A total of 942 participants from 99 countries were included for final analysis: 58% (n = 544) from Europe, 52% (n = 485) female, 43% (n = 409) ≤40 years old, and 36% (n = 343) of non-white ethnicity. In July/August 2020, 60% (n = 525) continued to report a change in professional duties compared with the pre-COVID-19 era. The proportion of participants at risk of poor well-being (33%, n = 310) and who reported feeling burnout (49%, n = 460) had increased significantly compared with April/May 2020 (25% and 38%, respectively; P < 0.001), despite improved job performance since COVID-19 (34% versus 51%; P < 0.001). Of those who had been tested for COVID-19, 8% (n = 39/484) tested positive; 18% (n = 7/39) felt they had not been given adequate time to recover before return to work. Since the pandemic, 39% (n = 353/908) had expressed concerns that COVID-19 would have a negative impact on their career development or training and 40% (n = 366/917) felt that their job security had been compromised. More than two-thirds (n = 608/879) revealed that COVID-19 has changed their outlook on their work-personal life balance. CONCLUSION: The COVID-19 pandemic continues to impact the well-being of oncology professionals globally, with significantly more in distress and feeling burnout compared with the first wave. Collective efforts from both national and international communities addressing support and coping strategies will be crucial as we recover from the COVID-19 crisis. In particular, an action plan should also be devised to tackle concerns raised regarding the negative impact of COVID-19 on career development, training, and job security.

The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series

Background: The ESMO Resilience Task Force has investigated wellbeing since COVID-19 in relation to work, lifestyle and support factors in oncology professionals globally. We reported on the significant impact of the initial surge of the pandemic on wellbeing and job performance (Banerjee et al. 2021). As the pandemic continues, it is imperative to understand experiences and concerns to better inform support measures for the oncology workforce. Methods: Three anonymous online surveys were conducted during the COVID-19 pandemic (S1, Apr/May 2020;S2, Jul/Aug 2020;S3, Feb/Mar 2021). Longitudinal analysis of responses at these timepoints were conducted. Here, we present responses to questions on job demands and resources, and perceived job performance since COVID-19 (JP-CV). Results: We analysed 3894 individual responses (S1, n=1520;S2, n=942;S3, n=1432): 53% (n=1961/3731) female, 45% (n=1679/3731) =/<40 years, 31% (n=1132/3692) non-white ethnicity, >100 countries. There has been significant increases from S1 to S3 (p<0.001) in feeling overwhelmed with workload (29% vs 45%);COVID-19-related clinical (14% vs 58%) and research (16% vs 64%) work;out-of-hours work (16% vs 41%), shift work (12% vs 26%) and overall working hours (17% vs 47%);and inadequate time for personal/family life (35% vs 45%). 59% (n=1156/1946) were unable to take allocated annual leave. While JP-CV has improved (34% vs 49%, p<0.001), there remained concerns about the negative impact of the pandemic on career development/training (43%), job security (37%) and international fellowship opportunities (76%). Overall, less than half had felt supported by their work management, professional societies or government, and/or had access to wellbeing support services. 25% (n=266/1086) were considering changing their future career with 38% (n=100/266) contemplating leaving the profession. Conclusions: Since COVID-19, oncology professionals have reported increased job demands, concerns over career development/training and job security, and inadequate time for personal life. There is a real threat of potential attrition in the current workforce. National and international stakeholders must act together to ensure robust recovery plans as we emerge from the COVID-19 crisis. Legal entity responsible for the study: The authors. Funding: ESMO. Disclosure: K.H.J. Lim: Financial Interests, Personal, Invited Speaker, Speaker honorarium: Janssen;Non-Financial Interests, Officer, Trainees committee representative for the North West deanery: Royal College of Physicians (UK);Non-Financial Interests, Officer, Trainees representative at the RCP Patient Safety Committee: Royal College of Physicians (UK);Non-Financial Interests, Officer, ACP representative at the RCP Student and Foundation Doctor Network (SFDN): Royal College of Physicians (UK);Non-Financial Interests, Officer, Trainees committee member: Association of Cancer Physicians (ACP) UK;Non-Financial Interests, Officer, Young Oncologists Committee (YOC): ESMO;Non-Financial Interests, Officer, Resilience Task Force (RTF): ESMO;Other, Currently funded by Wellcome-Imperial 4i Clinical Research Fellowship: Wellcome Trust. K. Punie: Other, Institutional, Other, institution received speaker fees or honoraria for consultancy/advisory roles: AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Novartis, Pfizer, Pierre Fabre, Hoffmann La Roche, Mundi Pharma, PharmaMar, Teva, Vifor Pharma;Other, Institutional, Research Grant: Sanofi;Other, Personal, Other, Travel support: AstraZeneca, Novartis, Pfizer, PharmaMar and Roche. C. Oing: Other, Personal, Other, research funding and honoraria: Roche;Other, Personal, Other, travel grant and honoraria: Medac Pharma and Ipsen Pharma;Other, Personal, Other, travel grant: PharmaMar. E. Elez: Other, Personal, Other, personal fees: Hoffman La - Roche, Bristol Myers Squibb, Servier, Amgen, Merck Serono, ArrayBiopharma, Sanof. T.M.S. Amaral: Other, Personal, Other, personal fees: Pierre Fabre and CeCaVa;Other, Personal, Other, personal fees and travel grants: BMS;Other, Perso al, Other, grants, personal fees and travel grants: Novartis;Other, Personal, Other, grants: Neracare, Sanofi and SkylineDx. P. Garrido Lopez: Other, Personal, Other, personal fees: Roche, MSD, BMS, Boerhinger-Ingelheim, Pfizer, AbbVie, Novartis, Lilly, AstraZeneca, Janssen, Blueprint Medicines, Takeda, Gilead, and ROVI. M. Lambertini: Other, Personal, Other, Consultant: Roche, AstraZeneca, Lilly and Novartis;Other, Personal, Other, Honoraria: Theramex, Roche, Novartis, Takeda, Pfizer, Sandoz, and Lilly. C.B. Westphalen: Other, Personal, Other, honoraria, travel support and advisory board: Bayer, BMS, Celgene, Roche, Servier, Shire/Baxalta, RedHil, and Taiho;Other, Personal, Other, speaker honoraria: Ipsen;Other, Personal, Advisory Board: GSK, Sirtex, and Rafael. J.B.A.G. Haanen: Other, Personal, Advisory Role, personal fees for advisory role: Neogene Tx;Other, Institutional, Other, grants and fees paid to institution: BMS, MSD, Novartis, BioNTech, Amgen;Other, Institutional, Other, fees paid to institution: Achilles Tx, GSK, Immunocore, Ipsen, Merck Serono, Molecular Partners, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm. C. Hardy: Other, Personal, Other, Director of a private company Hardy People Ltd.: Hardy People Ltd. S. Banerjee: Other, Institutional, Research Grant: AstraZeneca, Tesaro and GSK;Other, Personal, Other, Honoraria: Amgen, AstraZeneca, MSD, GSK, Clovis, Genmab, Merck Serono, Mersana, Pfizer, Seattle Genetics, and Tesaro. All other authors have declared no conflicts of interest.

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.

BACKGROUND: The impact of the coronavirus disease 2019 (COVID-19) pandemic on well-being has the potential for serious negative consequences on work, home life, and patient care. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set out to investigate well-being in oncology over time since COVID-19. METHODS: Two online anonymous surveys were conducted (survey I: April/May 2020; survey II: July/August 2020). Statistical analyses were performed to examine group differences, associations, and predictors of key outcomes: (i) well-being/distress [expanded Well-being Index (eWBI; 9 items)]; (ii) burnout (1 item from eWBI); (iii) job performance since COVID-19 (JP-CV; 2 items). RESULTS: Responses from survey I (1520 participants from 101 countries) indicate that COVID-19 is impacting oncology professionals; in particular, 25% of participants indicated being at risk of distress (poor well-being, eWBI ≥ 4), 38% reported feeling burnout, and 66% reported not being able to perform their job compared with the pre-COVID-19 period. Higher JP-CV was associated with better well-being and not feeling burnout (P < 0.01). Differences were seen in well-being and JP-CV between countries (P < 0.001) and were related to country COVID-19 crude mortality rate (P < 0.05). Consistent predictors of well-being, burnout, and JP-CV were psychological resilience and changes to work hours. In survey II, among 272 participants who completed both surveys, while JP-CV improved (38% versus 54%, P < 0.001), eWBI scores ≥4 and burnout rates were significantly higher compared with survey I (22% versus 31%, P = 0.01; and 35% versus 49%, P = 0.001, respectively), suggesting well-being and burnout have worsened over a 3-month period during the COVID-19 pandemic. CONCLUSION: In the first and largest global survey series, COVID-19 is impacting well-being and job performance of oncology professionals. JP-CV has improved but risk of distress and burnout has increased over time. Urgent measures to address well-being and improve resilience are essential.

The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration

Background: The impact of the COVID-19 (CV-19) pandemic on wellbeing has the potential for serious negative consequences on work, home life and patient care. The ESMO Resilience Task Force collaboration set out to investigate wellbeing in oncology over time since CV-19. Methods: 2 online surveys were conducted (survey I April/May;survey II July/August 2020). Statistical analyses were used to examine group differences, associations and to explore predictors of key outcomes: 1) wellbeing/distress (Wellbeing Index (WBI-9)), 2) burnout (1 item);and 3) CV-19 job performance (2 item CJP;standard of care and job delivery compared to pre-CV 19). Results: Survey I had 1520 participants from 101 countries. Responses indicate that CV-19 is impacting the oncology workforce resulting in a number of changes to work and personal lives. 25% were at risk of distress (poor wellbeing, WBI ≥4);38% reported feeling burnout and 66% were not able to perform their job compared to pre-CV-19. Higher CJP was significantly associated with better wellbeing and not feeling burnout (p<0.01). Differences were seen in wellbeing and CJP between countries (p<0.001) and related to CV-19 country mortality rate (p<0.05). The main predictors of wellbeing, burnout and CJP were resilience and changes to work hours. Others frequently identified were coping strategies, ethnicity, concern about training/career, worried about current wellbeing, and working conditions. In Survey II, results from 942 participants are undergoing analysis. Overall, comparisons between surveys show overall wellbeing and burnout rates have worsened overtime but CJP has improved. Among 272 participants who completed both surveys, WBI scores ≥4 (indicating higher risk of distress) and burnout rates were higher in survey II compared to survey I (22% vs 31% p=0.01;35% vs 49% p=0.001 respectively) suggesting wellbeing and burnout may be worsening overtime. CJP improved (38% vs 54% p<0.001). Conclusions: In the largest global survey series, COVID-19 is impacting on the wellbeing and job performance of oncology professionals. Risk of distress and burnout has increased over time. Urgent measures to address wellbeing and improve resilience are essential. Legal entity responsible for the study: ESMO. Funding: ESMO. Disclosure: S. Banerjee: Research grant/Funding (institution): AstraZeneca;Research grant/Funding (self): GSK;Honoraria (self): Amgen;Honoraria (self): AstraZeneca;Honoraria (self): MSD;Honoraria (self): GSK;Honoraria (self): Clovis;Honoraria (self): Genmab;Honoraria (self): Merck Serono;Honoraria (self): Mersana;Honoraria (self): Pfizer;Honoraria (self): Seattle Genetics;Honoraria (self): Tesaro. C. Oing: Research grant/Funding (institution): PharmaMar;Travel/Accommodation/Expenses: Ipsen;Travel/Accommodation/Expenses: PharmaMar;Travel/Accommodation/Expenses: Medac. K. Punie: Honoraria (self): AstraZeneca;Honoraria (self): Eli Lilly;Honoraria (self): Novartis;Honoraria (self): Pfizer;Honoraria (self): Pierre Fabre;Honoraria (self): Hoffmann La Roche;Honoraria (self): Vifor Pharma;Speaker Bureau/Expert testimony: Eli Lilly;Speaker Bureau/Expert testimony: Mundi Pharma;Speaker Bureau/Expert testimony: Novartis;Speaker Bureau/Expert testimony: Pfizer;Speaker Bureau/Expert testimony: Hoffmann La Roche;Honoraria (self): Teva;Research grant/Funding (institution): Sanofi;Travel/Accommodation/Expenses: AstraZeneca;Travel/Accommodation/Expenses: Novartis;Travel/Accommodation/Expenses: Pfizer;Travel/Accommodation/Expenses: PharmaMar;Travel/Accommodation/Expenses: Hoffmann La Roche. M. Lambertini: Advisory/Consultancy: Roche;Advisory/Consultancy: Novartis;Honoraria (institution): Theramex;Honoraria (institution): Takeda;Honoraria (institution): Roche;Honoraria (institution): Lilly;Honoraria (institution): Pfizer;Honoraria (institution): Novartis. C. Benedikt Westphalen: Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer;Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: Celge e;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Ipsen;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MedScape;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Rafael Pharmaceuticals;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: RedHIll;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Shire;Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Taiho;Research grant/Funding (institution): Roche. P. Garrido Lopez: Advisory/Consultancy: AbbVie;Speaker Bureau/Expert testimony: AstraZeneca;Advisory/Consultancy: BluePrint Medicine;Advisory/Consultancy, Speaker Bureau/Expert testimony: Boerhinger Ingelheim;Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS;Advisory/Consultancy: Gilead;Advisory/Consultancy: Guardant Health;Advisory/Consultancy: Janssen;Advisory/Consultancy: Lilly;Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD;Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis;Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer;Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche;Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda;Speaker Bureau/Expert testimony: Rovi;Speaker Bureau/Expert testimony: Sysmex. T.M.S. Amaral: Honoraria (self), Travel/Accommodation/Expenses: BMS;Honoraria (self), Travel/Accommodation/Expenses: Novartis;Honoraria (self): PIerre Fabre;Honoraria (institution): Neracare;Honoraria (institution): Sanofi. J.B.A.G. Haanen: Advisory/Consultancy: AIMM THerapeutics;Advisory/Consultancy: Amgen;Advisory/Consultancy: AZ;Advisory/Consultancy: Bayer;Advisory/Consultancy: BioNtech;Advisory/Consultancy: BMS;Advisory/Consultancy: GSK;Advisory/Consultancy: Gateta;Advisory/Consultancy: Immunocore;Advisory/Consultancy: Ipsen;Advisory/Consultancy: Merck Serono;Advisory/Consultancy: MSD;Advisory/Consultancy: Molecular Partners;Advisory/Consultancy: Roche;Advisory/Consultancy: Sanofi;Advisory/Consultancy: Seattle Genetics;Advisory/Consultancy: Third Rock Venture;Advisory/Consultancy: Vaximm;Research grant/Funding (institution): Neogene;Research grant/Funding (institution): Amgen;Research grant/Funding (institution): BMS;Research grant/Funding (institution): BIoNthech;Research grant/Funding (institution): MSD;Research grant/Funding (institution): Novartis;Advisory/Consultancy: Genentech. All other authors have declared no conflicts of interest.

Risk factors for death due to COVID-19, in the state of Acre, Brazil, 2020: a retrospective cohort study

OBJECTIVE: To analyze risk factors for death in individuals with severe acute respiratory syndrome due to COVID-19. METHODS: This was a retrospective cohort study, comprised of adult individuals with COVID-19, from March to September 2020, notified by the Epidemiological Surveillance System in the state of Acre, Brazil. Cox regression was used. RESULTS: Among 57,700 individuals analyzed, the incidence was 2,765.4/100,000 inhabitants, and mortality was, 61.8/100,000 inhabitants. The risk factors for death were: being male (HR=1.48 -95% CI 1.25;1.76), age >=60 years (HR=10.64 -95% CI 8.84;12.81), symptom of dyspnea (HR=4.20 -95% CI 3.44;5.12) and multimorbidity (HR=2.23 -95% CI 1.77;2.81), with emphasis on heart disease and diabetes mellitus. 'Sore throat' and 'headache' were symptoms present in mild cases of COVID-19. CONCLUSION: Being male, elderly, having heart disease, diabetes mellitus and dyspnea were characteristics associated with death due to COVID-19.

Implementation of Tele-ICU during the COVID-19 pandemic

OBJECTIVE: To describe the implementation of a Tele-ICU program during the COVID-19 pandemic, as well as to describe and analyze the results of the first four months of operation of the program. METHODS: This was a descriptive observational study of the implementation of a Tele-ICU program, followed by a retrospective analysis of clinical data of patients with COVID-19 admitted to ICUs between April and July of 2020. RESULTS: The Tele-ICU program was implemented over a four-week period and proved to be feasible during the pandemic. Participants were trained remotely, and the program had an evidence-based design, the objective being to standardize care for patients with COVID-19. More than 100,000 views were recorded on the free online platforms and the mobile application. During the study period, the cases of 326 patients with COVID-19 were evaluated through the program. The median age was 60 years (IQR, 49-68 years). There was a predominance of males (56%). There was also a high prevalence of hypertension (49.1%) and diabetes mellitus (38.4%). At ICU admission, 83.7% of patients were on invasive mechanical ventilation, with a median PaO2/FiO2 ratio < 150. It was possible to use lung-protective ventilation in 75% of the patients. Overall, in-hospital mortality was 68%, and ICU mortality was 65%. CONCLUSIONS: Our Tele-ICU program provided multidisciplinary training to health care professionals and clinical follow-up for hundreds of critically ill patients. This public health care network initiative was unprecedented and proved to be feasible during the COVID-19 pandemic, encouraging the creation of similar projects that combine evidence-based practices, training, and Tele-ICU.

Nursing care to COVID-19 patients on hemodialysis and in prone position: an experience report

OBJECTIVE: To describe the experience report of a nurse providing care to COVID-19 patients on hemodialysis and in prone position. METHOD: Experience report. This study was conducted in a philanthropic hospital in a Brazilian capital from May to August 2020 during the Coronavirus pandemic. RESULTS: The nurse has faced several challenges concerning structure, material, human resources, and care when treating COVID-19 patients on hemodialysis and in prone position. Management based on dialogue and shared evidence-based information and implementation of a new care protocol were a foundation for care reorganization of the Nursing team for providing care to COVID-19 patients. CONCLUSION: This experience emphasizes the importance of nursing care to patients' responses, with actions based on care protocols, strengthening human relations. The conduction of different study designs is necessary to contribute to an improved nursing care and survival of patients experiencing COVID-19 complications.

Risk factors for death by COVID-19, in Acre, Brazil, 2020: retrospective cohort

Objective: To analyze risk factors for death in individuals with Severe Acute Respiratory Syndrome by COVID-19. Methods: Retrospective cohort, with adult individuals with COVID-19, between March and September 2020, notified by Epidemiological Surveillance System in state of Acre, Brazil. Cox Regression was used. Results: Of the 57,700 individuals, the incidence was 2,765.4/100,000 inhabitants and mortality 61.8/100,000 inhabitants. The risk factors for death were: male gender (HR=1.48 - 95%CI 1.25;1.76), age >= 60 years old (HR=10.64 - 95%CI 8.84;12.81), dyspnea (HR=4.20 - 95%CI 3.44;5.12), multimorbidity (HR=2.23 - 95%CI 1.77;2.81), with emphasis heart problems and diabetes. The symptoms sore throat (HR=0.44 - 95%CI 0.27;0.71) and headache (HR=0.44 - 95%CI 0.22;0.89) were present in mild cases of the disease. Conclusion: Men, older adults, those with heart disease, diabetes and dyspnea were at risk of death in the occurrence by COVID-19.